EVD | Jotup

Cerence Drives Enhanced Intelligence, Including New Electric Vehicle Use Cases, in MBUX in the Mercedes-Benz EQS

Retrieved on:

星期三, 十二月 22, 2021

Building on the companies partnership on the next-gen MBUX introduced last year, MBUX in the Mercedes-Benz EQS features a new set of electric vehicle-related capabilities and use cases powered by Cerence that simplify the EV ownership experience for Mercedes-Benz EQS drivers.

Key Points:

Building on the companies partnership on the next-gen MBUX introduced last year, MBUX in the Mercedes-Benz EQS features a new set of electric vehicle-related capabilities and use cases powered by Cerence that simplify the EV ownership experience for Mercedes-Benz EQS drivers.
Cerence EVD uses the cars existing microphones to detect varying types and styles of emergency vehicle sirens accurately and reliably.
If a siren is detected during autonomous driving on a highway, the vehicle is steered to the side to make way for the emergency vehicle.
Whether its connected cars, autonomous driving, e-vehicles, or buildings, Cerence is mapping the road ahead.

$11+ Billion Respiratory Protection Equipment Markets - Global Forecasts from 2021 to 2026 - ResearchAndMarkets.com

Retrieved on:

星期三, 十一月 17, 2021

The "Respiratory Protection Equipment Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Respiratory Protection Equipment Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
The global respiratory protection equipment market is evaluated at US$ 6.879 billion for the year 2019 growing at a CAGR of 7.04% reaching the market size of US$ 11.076 billion by the year 2026.
Regulations by various governments involving workplace security are the major driving force for the global respiratory protection equipment market.
Several regulatory organizations have recommended various companies and governments to increase their manufacturing of respiratory protective equipment, including respirators and breathing apparatuses.

Ridgeback Biotherapeutics Responds to 13th Ebola Outbreak in Democratic Republic of Congo

Retrieved on:

星期三, 十月 20, 2021

Health, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Biomedical Advanced Research and Development Authority, Institut National pour la Recherche Biomedicale, Clinical trial, Severe acute respiratory syndrome coronavirus 2, Protalix BioTherapeutics, Democratic republic, Global Affairs Canada, NIAID, View, Death, Assistant, COVID-19, Institut national de recherche et de sécurité, Pharmacist, Antibody, PCR, VRC, Diagnosis, Merck, Contract, Collection, Senior, Data collection, Office of the Assistant Secretary for Preparedness and Response, Infection, Department, LP, United States Department of Health and Human Services, Ministry, CEO, VIR, Ansuvimab, EVD, Disease, Patient, Survival, DRC, Biodefense, Merck & Co., Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ministry of Health and Social Welfare, Liberia, Vaccine, Pharmaceutical industry

Ridgeback Biotherapeutics (Ridgeback Bio), a biotechnology company experienced in antiviral drug development including medicines to treat SARS-Cov-2 and Ebola, announces deployment of the Ridgeback Ebola Rapid Response team to the Democratic Republic of the Congo (DRC).

Key Points:

Ridgeback Biotherapeutics (Ridgeback Bio), a biotechnology company experienced in antiviral drug development including medicines to treat SARS-Cov-2 and Ebola, announces deployment of the Ridgeback Ebola Rapid Response team to the Democratic Republic of the Congo (DRC).
Ridgeback Bio is supporting a team of clinicians and pharmacists specialized in the treatment of Ebola Virus Disease (EVD) patients.
In order to achieve this, we have established the Ridgeback Ebola Rapid Response team which will work with our partners at the Institut National de Recherche in the Democratic Republic of the Congo.
Ridgeback Biotherapeutics markets EbangaTM for the treatment of Ebola and has a late-stage development pipeline which includes molnupiravir for the treatment of COVID-19.

Worldwide Respiratory Protective Equipment Industry to 2026 - Rapid Industrial Growth in Developing Economies Presents Opportunities - ResearchAndMarkets.com

Retrieved on:

星期四, 九月 16, 2021

What are the inhibiting factors and impact of COVID-19 shaping the Global Respiratory Protective Equipment Market during the forecast period?

Key Points:

What are the inhibiting factors and impact of COVID-19 shaping the Global Respiratory Protective Equipment Market during the forecast period?
Which are the products/segments/applications/areas to invest in over the forecast period in the Global Respiratory Protective Equipment Market?
What is the competitive strategic window for opportunities in the Global Respiratory Protective Equipment Market?
What modes and strategic moves are considered suitable for entering the Global Respiratory Protective Equipment Market?

inTRAvent’s Bedside Neuro-Navigation Device Receives FDA 510(k) Clearance

Retrieved on:

星期二, 九月 14, 2021

inTRAvent Medical Partners LP, a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, today announced FDA 510(k) clearance of its SOLOPASS system for aiding in the frontal placement of intra-ventricular catheters.

Key Points:

inTRAvent Medical Partners LP, a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, today announced FDA 510(k) clearance of its SOLOPASS system for aiding in the frontal placement of intra-ventricular catheters.
Without the aid of contemporary guidance technologies, these conditions make bedside EVD placement challenging even for highly skilled practitioners.
SOLOPASS allows caregivers to visualize the ventricular system, deep within the brain, to enable precision planning and guidance.
inTRAvent Medical Partners is a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve the safety and efficacy of neurosurgical procedures.

Antler Gold Appoints Christopher Drysdale as Vice President and Provides Exploration Update on Its Erongo Gold Project, Central Namibia

Retrieved on:

星期二, 二月 16, 2021

Medical specialties, Continents, Infectious diseases, West African Ebola virus epidemic, Biological weapons, Tropical diseases, Zoonoses, Ebola, Antler, EVD, GUINEA

Christopher was previously Antler's Manager of Corporate Development and was directly responsible for Antler having the opportunity to secure the Erongo Project.

Key Points:

Christopher was previously Antler's Manager of Corporate Development and was directly responsible for Antler having the opportunity to secure the Erongo Project.
Antler also provides an update on exploration currently underway on the project.
Antler Gold Inc. (TSXV: ANTL) is a Canadian company, focused on the acquisition and exploration of gold projects in Namibia.
For further information, please contact Daniel Whittaker, President and CEO of Antler Gold Inc., at (902) 488-4700.

Ebola virus disease in Nzérékoré – Guinea

Retrieved on:

星期二, 二月 16, 2021

Medical specialties, Medicine, Health sciences, Zoonoses, West African Ebola virus epidemic, Biological weapons, Tropical diseases, Ebola, Zaire ebolavirus, Virus, EVD, Western African Ebola virus epidemic

On 14 February 2021, an Ebola virus disease (EVD) outbreak was declared in the rural area of Gouk in NZerekore region, Guinea, by national health authorities.

Key Points:

On 14 February 2021, an Ebola virus disease (EVD) outbreak was declared in the rural area of Gouk in NZerekore region, Guinea, by national health authorities.
Samples from the confirmed cases have been sent to the Institut Pasteur in Senegal for full genome sequencing in order to identify the strain of the Ebola virus.
Significant developments have been made in the prevention of Ebola virus disease, with two vaccines now licensed for use in several countries.
For other EU/EEA citizens living in or travelling through Guinea, the likelihood of exposure is very low, as is the likelihood of introduction and further spread of the Ebola virus within the EU/EEA.

Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease

Retrieved on:

星期五, 十月 18, 2019

If affirmed by the European Commission, the vaccine will be authorized under the brand name ERVEBO (pronounced UR-VEE-BOH) and indicated for active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus.

Key Points:

If affirmed by the European Commission, the vaccine will be authorized under the brand name ERVEBO (pronounced UR-VEE-BOH) and indicated for active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus.
This positive opinion from CHMP represents important progress towards licensure of a vaccine to provide protection from Ebola virus disease to people in areas affected by the Ebola Zaire virus, said Dr. Roger M. Perlmutter, president, Merck Research Laboratories.
In September 2019, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) and granted priority review for V920.
In late 2014, when the Ebola outbreak in western Africa was at its peak, Merck licensed V920 from NewLink Genetics.

AHF Urges Transparency from Tanzania on Ebola

Retrieved on:

星期二, 十月 1, 2019

General Health, Infectious diseases, Health, Pharmaceutical, Health, Articles, Contents, West African Ebola virus epidemic, Ebola virus disease, RTT, International Health Regulations, EVD, Équateur province Ebola outbreak, In Sierra Leone

WHO also reported it received an unofficial notification that the deceased individual tested positive for Ebola and about the presence of two new suspected cases.

Key Points:

WHO also reported it received an unofficial notification that the deceased individual tested positive for Ebola and about the presence of two new suspected cases.
Failure by Tanzania to release critical details about the suspected Ebola cases violates International Health Regulations (IHR) standards, which stipulates that "EVD/suspected EVD is a notifiable disease" as a potential public health emergency.
"The government of Tanzania needs to understand that there is much at stake, and their lack of transparency on Ebola puts its citizens, neighbouring countries and the entire global community at risk," said AHF Africa Bureau Chief Dr. Penninah Iutung.
When it comes to serious health threats like Ebola, we all live in one, united worldwithout borders."

KT Partners with Ghana Gov't for Epidemic Preparedness

Retrieved on:

星期四, 十一月 22, 2018

Medicine, West African Ebola virus epidemic, Health, Veterinary medicine, Government of Ghana, Ghana Health Service, Nsiah Asare, Ebola virus disease, EVD

Attendees at the signing ceremony in Accra, Ghana, included Yoon Jong-Jin, KT's senior executive vice president in charge of public relations and Dr. Anthony Nsiah Asare, director-general of Ghana Health Service (GHS).

Key Points:

Attendees at the signing ceremony in Accra, Ghana, included Yoon Jong-Jin, KT's senior executive vice president in charge of public relations and Dr. Anthony Nsiah Asare, director-general of Ghana Health Service (GHS).
Other key figures are Kim Sung-Soo, Ambassador of Korean Embassy of Ghana, Michael Melchior, Country Director of U.S. Centers for Disease Control and Prevention (CDC) Ghana, Dr. Owen Laws Kaluwa, Ghana Country Representative of the World Health Organization (WHO), Fiachra McAsey, Deputy Representative of UNICEF Ghana, and Mr. Yukyum Kim, Country Director of KOICA Ghana.
In 2014-16, the region suffered the most widespread Ebola virus epidemic in recorded history, while there is no confirmed Ebola Virus Disease (EVD) case in Ghana to date, according to the WHO.
KT dispatched volunteer IT workers to Laos together with the KOFIH and KT Group Hope Sharing Foundation, the company's social contribution organization, from November 11-17.